Protocol Ledger

NCT03385564 · Phase II · COMPLETED

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Interventional Phase II clinical trial protocol NCT03385564 sponsored by Boehringer Ingelheim in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-09 Enrollment: 69 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03385564
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)69 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03385564
Protocol FieldVerified Registry Value
NCT IdentifierNCT03385564
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment69 participants (ACTUAL)
Registered Start Date2018-01-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03385564
Hospital Research SiteLocationSite Profile
Columbia University Irving Medical CenterNew York, NYOpen Hospital Dossier ->
Princess Alexandra HospitalWoolloongabba, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI